Technical analysis of InflaRx N.V. (IFRX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases.
Price Performance
| 1 month | -6.42% |
| 3 months | +12.71% |
| Year-to-date | +101.98% |
| 1 year | +72.88% |
| 3 years | -42.37% |
| 5 years | -25.27% |
52-Week Range
| 52-week High | $2.95 |
| 52-week Low | $0.80 |
| Avg Volume (90d) | 1.2M |
Technical Indicators
| SMA 50 | $2.00 |
| SMA 200 | $1.54 |
| Beta | 1.51 |
| 30-day Volatility (annualised) | 75.1% |
| Price vs SMA 50 | +2.1% |
| Price vs SMA 200 | +32.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.46 | |
| 2025-11 | $1.26 | -13.7% |
| 2025-12 | $1.01 | -19.8% |
| 2026-01 | $0.88 | -12.7% |
| 2026-02 | $0.92 | +4.3% |
| 2026-03 | $0.89 | -2.8% |
| 2026-04 | $2.07 | +131.4% |
| 2026-05 | $2.40 | +15.9% |
| 2026-06 | $2.24 | -6.7% |
| 2026-07 | $1.70 | -24.1% |
| 2026-08 | $2.13 | +25.3% |
| 2026-09 | $2.04 | -4.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $2.04 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | DE |
Valuation Ratios
| Price / Book | 1.38 |
| EV / EBITDA | -3.32 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 8.22 |